Compare LXEO & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LXEO | CUVL |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | | Miscellaneous |
| Sector | | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.7M | 374.2M |
| IPO Year | 2023 | 2004 |
| Metric | LXEO | CUVL |
|---|---|---|
| Price | $3.19 | $5.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $20.67 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 5.2K |
| Earning Date | 11-16-2026 | 08-27-2026 |
| Dividend Yield | N/A | ★ 0.56% |
| EPS Growth | ★ 39.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $654,000.00 | N/A |
| Revenue This Year | N/A | $0.47 |
| Revenue Next Year | N/A | $6.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $4.81 |
| 52 Week High | $10.99 | $8.20 |
| Indicator | LXEO | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 43.75 |
| Support Level | $2.72 | $4.86 |
| Resistance Level | $3.56 | $6.00 |
| Average True Range (ATR) | 0.38 | 0.26 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 25.62 | 21.54 |
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.